Studies that utilise real-world evidence consolidate relations with clinicians
Studies relying on real-world evidence help clinicians to create a better overall picture of the situation of patients.
Why should a clinician start cooperation with a pharmaceutical company in research based on real world data (RWD)? Does it benefit the treatment of patients, or does it just take time from patient work?
According to Medaffcon’s RWE Lead Mariann Lassenius, the benefits received by a clinician and a clinic from participating in a study are clear and support the treatment of patients.
First of all, real-world evidence (RWE) studies provide the clinicians with a possibility to conduct research and receive resources for it. In studies conducted with a pharmaceutical company, clinicians have a team of competent professionals at their disposal. They can design a study based on RWE and review the data.
According to Lassenius, the results of RWE studies are without exception very interesting from the clinicians’ perspective. They help to create an overall picture of the patients’ treatment and situation, which is often lacking. This makes it possible to observe, for example, how well current care guidelines are actually realised and whether the patients have treatment-related needs that aren’t currently fulfilled.
– Clinics and clinicians can utilise this information in patient work, tells Lassenius.
Terveystalo develops the treatment of migraine on the basis of data analysis
One example of this sort of study and the utilisation of its results is a study conducted in cooperation by Terveystalo, Novartis, and Medaffcon on the treatment of migraine patients. On the basis of its results, Terveystalo started to develop the treatment of migraine patients in many different manners.
A study conducted by Takeda and Medaffcon, in turn, revealed that data on the survival and the number of patients with multiple myeloma were incomplete at the level of Finland.
The key is to always remember the nature of RWE.
– RWE studies are not effectiveness studies, but help to study the impact of treatments, Lassenius reminds. The objectives of the study are, however, often wider than this: examples of study interests include characterisation of patients, treatment paths, and the real-life treatment as well as the use of healthcare resources, that is, costs.
Read more about Medaffcon’s RWE studies and services.